Shares of Cardiol Therapeutics Inc. (OTCMKTS:CRTPF – Get Free Report) shot up 8.9% on Wednesday . The company traded as high as $2.19 and last traded at $2.15. 2,124,510 shares were traded during trading, an increase of 3,066% from the average daily volume of 67,097 shares. The stock had previously closed at $1.9750.
Cardiol Therapeutics Price Performance
The company has a 50-day simple moving average of $1.36 and a 200-day simple moving average of $1.25.
About Cardiol Therapeutics
Cardiol Therapeutics Inc is a clinical-stage biotechnology company focused on the development of novel immuno-lipid therapies for treating heart failure and inflammation-related cardiovascular diseases. The company’s proprietary platform is built on synthetic formulations of cardiolipin, a naturally occurring mitochondrial lipid known to play a key role in cellular energy production and inflammatory regulation. By harnessing the anti-inflammatory properties of cardiolipin derivatives, Cardiol aims to address unmet needs in acute and chronic cardiovascular conditions.
Cardiol’s lead product candidate, CT-1 Microspheres, is designed for intravenous administration to hospitalized patients with acute decompensated heart failure.
See Also
- Five stocks we like better than Cardiol Therapeutics
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
